Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?

Area of Science:

• Pharmacology
• Clinical Medicine
• Evidence-Based Practice

Background:

• Gabapentin is frequently prescribed in the U.S. for various off-label uses, often as a substitute for opioid pain relief.
• Growing concerns exist regarding gabapentin's safety profile, particularly its potential association with substance abuse when combined with opioids.

Purpose of the Study:

• To critically evaluate the efficacy and risk-benefit profile of gabapentin across its diverse off-label indications.
• To address the safety concerns surrounding gabapentin use, especially in conjunction with opioid therapy.

Main Methods:

• Systematic review and critical appraisal of existing literature on gabapentin's off-label uses.
• Analysis of evidence from high-quality studies versus uncontrolled trials and case reports.

Main Results:

• Reviews of off-label indications, including migraine, fibromyalgia, mental illness, and substance dependence, revealed modest or no significant clinical benefits.
• High-quality evidence supporting gabapentin's efficacy in these areas is frequently overshadowed by lower-quality studies and anecdotal reports.

Conclusions:

• Clinicians must carefully assess the evidence for gabapentin's efficacy for specific indications due to questionable risk-benefit.
• Further large-scale, high-quality research is essential to accurately determine gabapentin's effectiveness in its numerous off-label applications.